Lineage Cell Therapeutics (LCTX) Acquisitions (2010 - 2019)
Lineage Cell Therapeutics' (LCTX) quarterly Acquisitions came in at $3.1 million in Q1 2019, up 966.05% quarter-over-quarter from $292387.0 in Q2 2012.
Lineage Cell Therapeutics (LCTX) Acquisitions (2010 - 2019) Analysis & Trends
Lineage Cell Therapeutics' Acquisitions history runs 4 years deep, the most recent figure standing at $3.1 million for Q1 2019.
- On a quarterly basis, Acquisitions changed N/A year-over-year to $3.1 million in Q1 2019; TTM through Dec 2019 was $3.1 million, a N/A change from a year earlier, with the FY2019 full-year figure at $3.1 million, changed N/A from the prior year.
- Acquisitions grew to $3.1 million in Q1 2019 per LCTX's latest filing, from $292387.0 in the prior quarter.
- Across five years, Acquisitions topped out at $3.1 million in Q1 2019 and bottomed at $3.1 million in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 267.08 Mn | 203.18 Mn | 1.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 3.12 Mn |
| Jun 30, 2012 | 292,387.00 |
| Sep 30, 2011 | 240,942.00 |
| Jun 30, 2011 | -240,942.00 |
| Mar 31, 2011 | 246,850.00 |
| Dec 31, 2010 | 222,766.00 |